- Sharing Vertex’s track record for serial innovation in manufacturing to create transformative medicines for people with serious diseases and high unmet medical needs
- Highlighting Vertex’s success with small molecule continuous manufacturing
- Transforming manufacturing in cell and genetic therapies for Sickle Cell Disease, Beta Thalassemia, and Type 1 Diabetes
- Describing the specific technical innovations and breakthroughs that have been instrumental in Vertex’s manufacturing success
- Emphasizing the importance of cross-functional collaboration to drive manufacturing innovations and deliver transformative medicines
Ciaran Brady
Vice President, Manufacturing Science and Technology
Vertex Therapeutics
Ciaran joined Vertex in 2021 and is the Vice President of MSAT, which provides technical leadership within the commercial manufacturing organization. This includes partnering with the R&D teams to develop and implement robust and scalable processes that are capable of reliably supplying patients with high quality medicines. The team also directly support the manufacturing sites to resolve complex technical issues and implement new technologies and technical agendas to drive continuous improvement.
Ciaran previously worked at Human Genome Sciences, Eli Lilly and Co. and Bristol-Myers Squibb in roles of increasing responsibility and has over 20 years of industry experience in manufacturing and process development, primarily for biologic medicines. During his career, he has directly contributed to the successful approvals, launches and supply of medicines such as Benlysta, Trulicity, Taltz, Opdivo and Orencia.
Ciaran is a native of Ireland and earned bachelor’s and Ph.D. degrees in Biotechnology from Dublin City University in Ireland. He subsequently moved to the U.S. to undertake a post-doctoral program in vaccine process development at the National Institutes of Health in Bethesda, MD.
